Jessica Cantrell, Ph.D. - Publications

Affiliations: 
2009 Cancer Biology University of Arizona, Tucson, AZ 
Area:
Oncology, Immunology

11 high-probability publications. We are testing a new system for linking publications to authors. You can help! If you notice any inaccuracies, please sign in and mark papers as correct or incorrect matches. If you identify any major omissions or other inaccuracies in the publication list, please let us know.

Year Citation  Score
2010 Cantrell J, Larmonier C, Janikashvili N, Bustamante S, Fraszczak J, Herrell A, Lundeen T, J LaCasse C, Situ E, Larmonier N, Katsanis E. Signaling pathways induced by a tumor-derived vaccine in antigen presenting cells. Immunobiology. 215: 535-44. PMID 19880213 DOI: 10.1016/J.Imbio.2009.09.006  0.676
2008 Larmonier N, Janikashvili N, LaCasse CJ, Larmonier CB, Cantrell J, Situ E, Lundeen T, Bonnotte B, Katsanis E. Imatinib mesylate inhibits CD4+ CD25+ regulatory T cell activity and enhances active immunotherapy against BCR-ABL- tumors. Journal of Immunology (Baltimore, Md. : 1950). 181: 6955-63. PMID 18981115 DOI: 10.4049/Jimmunol.181.10.6955  0.622
2008 Li G, Andreansky S, Helguera G, Sepassi M, Janikashvili N, Cantrell J, Lacasse CL, Larmonier N, Penichet ML, Katsanis E. A chaperone protein-enriched tumor cell lysate vaccine generates protective humoral immunity in a mouse breast cancer model. Molecular Cancer Therapeutics. 7: 721-9. PMID 18347157 DOI: 10.1158/1535-7163.Mct-07-2067  0.662
2008 Larmonier N, Cantrell J, Lacasse C, Li G, Janikashvili N, Situ E, Sepassi M, Andreansky S, Katsanis E. Chaperone-rich tumor cell lysate-mediated activation of antigen-presenting cells resists regulatory T cell suppression. Journal of Leukocyte Biology. 83: 1049-59. PMID 18174364 DOI: 10.1189/Jlb.0907635  0.626
2007 Larmonier N, Marron M, Zeng Y, Cantrell J, Romanoski A, Sepassi M, Thompson S, Chen X, Andreansky S, Katsanis E. Tumor-derived CD4(+)CD25(+) regulatory T cell suppression of dendritic cell function involves TGF-beta and IL-10. Cancer Immunology, Immunotherapy : Cii. 56: 48-59. PMID 16612596 DOI: 10.1007/S00262-006-0160-8  0.75
1987 Ribi E, Cantrell JL, Myers KR. 3. Enhancement of tumor immunity with bacterial adjuvants Journal of Industrial Microbiology. 19-29.  0.349
1982 Lichtenstein A, Tuttle R, Cantrell J, Zighelboim J. Effects of different fractions of Corynebacterium parvum on the cytotoxic T-cell response to alloantigens in mice Journal of the National Cancer Institute. 69: 495-501. PMID 6213807  0.379
1979 Cantrell JL, McLaughlin CA, Ribi E. Efficacy of Tumor Cell Extracts in lmmunotherapy of Murine EL-4 Leukemia Cancer Research. 39: 1159-1167. PMID 421199  0.332
1979 Cantrell JL, Wheat RW. Antitumor Activity and Lymphoreticular Stimulation Properties of Fractions Isolated from Corynebacterium parvum Cancer Research. 39: 3554-3563. PMID 225023  0.321
1978 Cantrell JL, Ribi E, McLaughlin CA. Passive transfer of tumor immunity with spleen cells from guinea pigs cured of hepatocarcinoma by nonspecific immunotherapy Cancer Immunology Immunotherapy. 4: 21-28. DOI: 10.1007/BF00205566  0.362
1975 Killion JJ, LeFever A, Cantrell JL. Immunotherapy of L1210 leukemia with isolated, antigenic subpopulations of L1210 cells Proceedings of the American Association For Cancer Research. 16.  0.336
Show low-probability matches.